News | June 21, 2021
Zydus and Bayer announce extension of their JV
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
Subscribe To Our Newsletter & Stay Updated
